ALUMIS INC. ALMS

Alumis Inc. is currently operating as a high cost research enterprise rather than a cash generating commercial business. The latest financial filings for the period ending March 2026 show a severe imbalance between scientific expenditure and customer sales. The company generated just $1.7 million in revenue while posting an operating loss of $98.4 million. This is the central story of the asset today: a massive capital outlay aimed at a future breakthrough, funded by shareholders who are currently absorbing a net loss of $93.1 million.

The underlying tension sits entirely on the balance sheet and the rate of cash consumption. While Alumis holds $671.6 million in total assets, its actual cash and cash equivalents sit at just $63.9 million. This liquidity position is highly precarious when measured against the $87.1 million in net cash used in operating activities during the same period. The business is burning through its liquid reserves to sustain an $81.5 million research and development habit.

Recent corporate filings reflect a company attempting to maintain standard governance rhythms while navigating this severe cash burn. In May 2026, Alumis distributed its annual report to security holders and filed additional proxy soliciting materials, alongside routine Form 4 insider transaction disclosures. These documents keep the administrative wheels turning for the 125.1 million diluted shares outstanding, but they do not solve the fundamental math problem. With diluted earnings per share at negative $0.74, the company must either find immediate commercial traction or secure fresh funding.

What remains unproven is whether the heavy R&D expenditure will yield a product capable of covering the corporate overhead. The $164,000 spent on acquiring property and equipment suggests a light physical footprint, meaning the vast majority of capital is flowing into intellectual property and clinical development. Until those investments convert into significant revenue streams, Alumis will remain a binary bet on future scientific success rather than a stable equity holding.